Form 4: Madrigal Pharmaceuticals Director Exercises Options and Sells Shares Under Pre-Arranged Plan

A director at Madrigal Pharmaceuticals, Rebecca Taub, exercised stock options and subsequently sold shares totaling 29,101 shares over two days in July 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Summary

• Rebecca Taub, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), engaged in transactions involving the company's common stock on July 16 and July 17, 2025.
• On July 16, 2025, Taub exercised stock options to acquire 26,444 shares of common stock at an exercise price of $9.45 per share.
• Immediately following the option exercise on July 16, 2025, Taub sold all 26,444 acquired shares at weighted average prices ranging from $350.1903 to $356.5248 per share.
• On July 17, 2025, Taub exercised additional stock options to acquire 2,657 shares of common stock at an exercise price of $9.45 per share.
• Concurrently on July 17, 2025, Taub sold all 2,657 acquired shares at weighted average prices ranging from $350.0908 to $351.4967 per share.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Taub on March 14, 2025.
• Following these transactions, Taub directly beneficially owns 461,044 shares of common stock.
• Additionally, 655,540 shares are indirectly beneficially owned by SQN LLC, where Taub and her spouse are managing members, with Taub disclaiming beneficial ownership except for her pecuniary interest.
• Remaining stock options exercisable at $9.45 per share, expiring on July 22, 2026, total 47,463.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that these sales were conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic selling based on negative undisclosed information. The high sale prices also reflect strong company valuation at the time of transaction.

Positives

• The exercise of stock options at a low price ($9.45) and subsequent sale at significantly higher market prices (around $350-$356) indicates a substantial gain for the reporting person.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing equity holdings rather than a reaction to immediate market conditions or undisclosed information.

Negatives

• The sale of a significant number of shares by a director, even under a 10b5-1 plan, could be perceived by some investors as a reduction in insider exposure to the company's stock.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details routine insider transactions under a pre-arranged trading plan, which is common practice for executives and directors to manage their equity compensation and personal finances. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sectors.

Comparison to Industry Standards

• This Form 4 filing, detailing insider stock transactions, does not provide information suitable for direct comparison to global industry benchmarks, specific comparable companies, projects, or results. Insider trading activity, especially when conducted under a Rule 10b5-1 plan, is a standard practice for managing equity compensation.

Related Party Transactions

• Rebecca Taub and her spouse are managing members of SQN LLC, which indirectly holds 655,540 shares of Madrigal Pharmaceuticals common stock. Taub disclaims beneficial ownership of these shares except to the extent of her pecuniary interest.

Stakeholder Impact

• Shareholders: The transactions represent a director monetizing equity compensation, which is a routine event. The pre-arranged nature of the sales under a 10b5-1 plan reduces the likelihood of negative signaling to other shareholders.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

Keywords

Madrigal Pharmaceuticals, MDGL, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, Director Transactions, Equity Sales, Biotechnology, Pharmaceuticals